The clinical and economic value of lovastatin in the primary prevention of cardiovascular disease
HMGCoA-inhibitors (statins) lower plasma cholesterol through interference with the rate-limiting enzyme in the endogenous synthesis process. Since their introduction in the early 90’s, the clinical attitude towards cardiovascular (cv) risk reduction has evolved from the attention to single risk fact...
Main Authors: | Lorenzo Pradelli, Orietta Zaniolo |
---|---|
Format: | Article |
Language: | English |
Published: |
SEEd Medical Publishers
2006-09-01
|
Series: | Farmeconomia: Health Economics and Therapeutic Pathways |
Subjects: | |
Online Access: | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/261 |
Similar Items
-
Lovastatin: a new “ancient” molecule for hypercholesterolaemia/dyslipidaemia treatment
by: Gianlorenzo Imperiale, et al.
Published: (2008-06-01) -
Regulatory Effects of Statins on SIRT1 and Other Sirtuins in Cardiovascular Diseases
by: Danial Khayatan, et al.
Published: (2022-05-01) -
Lovastatin for adult patients with dengue: protocol for a randomised controlled trial
by: Whitehorn James, et al.
Published: (2012-10-01) -
The role of statins in clinical medicine -LDL - cholesterol lowering and beyond
by: Swiss Medical Weekly
Published: (2006-01-01) -
Improved methanol-derived lovastatin production through enhancement of the biosynthetic pathway and intracellular lovastatin efflux in methylotrophic yeast
by: Yiqi Liu, et al.
Published: (2018-05-01)